# Equity, diversity, and inclusion in oncology pharmacy practice: Everyone's business

## TL;DR

This paper explores equity, diversity, and inclusion issues in oncology pharmacy, highlighting microaggressions and lack of diversity in leadership.

## Contribution

It presents community-led research on EDI in oncology pharmacy, emphasizing real-world experiences and actionable insights.

## Key findings

- Racial and ethnic microaggressions were the most reported by participants.
- Lack of diversity in senior roles and workplace exclusion were commonly described.
- Discrimination impacts extend to patient care, underscoring the need for EDI improvements.

## Abstract

Equity, Diversity, and Inclusion (EDI) is gaining increased attention within all industries healthcare being no exception. The terminology Equity, Diversity, and Inclusion and its abbreviation EDI gained popularity in the early 2000's when varied socio-political factors prompted many organisations to examine EDI concepts and how to operationalise them. The growing diversity of our society requires cross-cultural inclusive approaches to increase equity and access to services.

This unique research is community-led research supported by the British Oncology Pharmacy Association, in which the members of the BOPA community are equal partners to inform action on policies that address EDI. This research was a cross-sectional study involving an online survey of financial BOPA members.

Demographic data was extracted, and the quotes were analysed for common themes. The majority of respondents were women, and the largest age group was between 34 and 44. The first cause of microaggressions identified by the respondents was of racial and ethnic origin, followed by marital status and religious nature. Participants described the lack of diversity in senior positions and the microaggressions experienced by those who hold leadership positions. Some participants described how some situations at work made them feel excluded or alienated. The impact of discrimination and bullying/microaggressions extended to patients was also reported.

Despite strategic directions encompassing this aspect, this research underscores the pressing need for more evidence on the lack of EDI in healthcare institutions. Our findings, located in the pharmacy oncology specialty, have identified the problem and highlighted the potential benefits of addressing it. More needs to be done in training and professional development to address unconscious bias and change behaviours.